Article

Evolutionary sequence modeling for discovery of peptide hormones.

SRI International, Menlo Park, California, United States of America.
PLoS Computational Biology (impact factor: 5.22). 02/2009; 5(1):e1000258. DOI:10.1371/journal.pcbi.1000258 pp.e1000258
Source: PubMed

ABSTRACT There are currently a large number of "orphan" G-protein-coupled receptors (GPCRs) whose endogenous ligands (peptide hormones) are unknown. Identification of these peptide hormones is a difficult and important problem. We describe a computational framework that models spatial structure along the genomic sequence simultaneously with the temporal evolutionary path structure across species and show how such models can be used to discover new functional molecules, in particular peptide hormones, via cross-genomic sequence comparisons. The computational framework incorporates a priori high-level knowledge of structural and evolutionary constraints into a hierarchical grammar of evolutionary probabilistic models. This computational method was used for identifying novel prohormones and the processed peptide sites by producing sequence alignments across many species at the functional-element level. Experimental results with an initial implementation of the algorithm were used to identify potential prohormones by comparing the human and non-human proteins in the Swiss-Prot database of known annotated proteins. In this proof of concept, we identified 45 out of 54 prohormones with only 44 false positives. The comparison of known and hypothetical human and mouse proteins resulted in the identification of a novel putative prohormone with at least four potential neuropeptides. Finally, in order to validate the computational methodology, we present the basic molecular biological characterization of the novel putative peptide hormone, including its identification and regional localization in the brain. This species comparison, HMM-based computational approach succeeded in identifying a previously undiscovered neuropeptide from whole genome protein sequences. This novel putative peptide hormone is found in discreet brain regions as well as other organs. The success of this approach will have a great impact on our understanding of GPCRs and associated pathways and help to identify new targets for drug development.

0 0
 · 
0 Bookmarks
 · 
45 Views
  • Article: The sequence of the human genome
    Science. 01/2001; 291:1304-1351.
  • Article: GPCR drug discovery: novel ligands for CNS receptors.
    [show abstract] [hide abstract]
    ABSTRACT: G protein-coupled receptors (GPCRs) are the largest class of cell surface receptors in humans. They convey extracellular signals into the cell interior by activating intracellular processes such as heterotrimeric G protein-dependent signaling pathways. They are widely distributed in the nervous system, and mediate key physiological processes including cognition, mood, appetite, pain and synaptic transmission. With at least 30% of marketed drugs being GPCR modulators, they are a major therapeutic target in the pharmaceutical industry's drug discovery programs. This review will survey recently patented ligands for GPCRs implicated in CNS disorders, in particular the metabotropic glutamate, adenosine and cannabinoid receptors. Metabotropic glutamate receptors regulate signaling by glutamate, the major excitatory brain neurotransmitter, while adenosine is a ubiquitous neuromodulater mediating diverse physiological effects. Recent patents for ligands of these receptors include mGluR5 antagonists and adenosine A(1) receptor agonists. Cannabinoid receptors remain one of the most important GPCR drug discovery target due to the intense interest in CB(1) receptor antagonists for treating obesity and metabolic syndrome. Such small molecule ligands are the outcome of the continuing focus of many pharmaceutical companies to identify novel GPCR agonist, antagonist or allosteric modulators useful for CNS disorders, for which more effective drugs are eagerly awaited.
    Recent Patents on CNS Drug Discovery 07/2007; 2(2):107-12.
  • Article: Novel neurotransmitters as natural ligands of orphan G-protein-coupled receptors
    [show abstract] [hide abstract]
    ABSTRACT: The ‘orphan’ G-protein-coupled receptors (GPCRs) are cloned GPCRs that bind unknown ligands. Since 1995, nineteen orphan GPCRs have been used as targets to identify and isolate their natural ligands via the application of the ‘orphan receptor strategy’. These ligands are peptides, lipids or biogenic amines, and act as transmitter molecules. One nucleotide–sugar derivative and six peptides or peptide families identified through this strategy are novel and have already enriched our understanding of various brain functions.
    Trends in Neurosciences 05/2001; · 14.23 Impact Factor

Full-text (2 Sources)

View
8 Downloads
Available from
14 Dec 2012

Keywords

44 false positives
 
basic molecular biological characterization
 
computational methodology
 
cross-genomic sequence comparisons
 
drug development
 
evolutionary probabilistic models
 
four potential neuropeptides
 
functional-element level
 
great impact
 
hierarchical grammar
 
HMM-based computational approach
 
hypothetical human
 
initial implementation
 
models spatial structure
 
new functional molecules
 
new targets
 
priori high-level knowledge
 
species comparison
 
temporal evolutionary path structure
 
undiscovered neuropeptide